DEMYELINATION is an important pathological process affecting nerve fibres. It is characterized histologically by destruction of the myelin sheath with preservation of axis cylinder continuity.

Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics ...

Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics ...

Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological diseases, announced today it has received clinical trial ...

Developed under an exclusive worldwide licence agreement with UCB, PTD802 is designed to counteract the effects of ...

Pheno Therapeutics Limited has received clinical trial authorisation (CTA) from the UK’s MHRA for its lead candidate, PTD802.

“The ability of IRX4204 to inhibit and functionally repair brain demyelination opens opportunities for potentially reparative treatment of brain damage in other types of neurologic conditions in ...

New research findings dispel the dogma that slower hyponatremia correction is better. Faster correction of severe hyponatremia is associated with a lower death rate, investigators report.